| Drug Class | MOA | ADME | Clinical Signs | Treatment |
|---------------------|-------------------------------|----------------------------|-----------------------------------|--|
| Antidepressants and | General goal of increasing | Most are rapidly absorbed | CNS: Agitation, restlessness, | Decontamination |
| Anxiolytic Drugs | the NT serotonin and | and have a rapid onset of | vocalization | Emesis and activated charcoal with |
| (Fluoxetine, | norepinephrine by blocking | action | GI: V/D, salivation, abdo pain | cathartic |
| Citalopram, | their reuptake or decreasing | Many come as extended | Neuro: Muscle rigidity, tremors, | IVF: hyperthermia |
| Paroxetine) | their breakdown | release | ataxia, shivering | B-blockers: Tachycardia and |
| | | | CV: tachycardia, hypertension | hypertension |
| | 5-HTP > serotonin > | | Misc. Sweating, hyperthermia, | Methocarbamol: Tremors |
| | Serotonin Syndrome | | tachypnea, transient blindness | Diazepam: Seizures |
| | | | *Serotonin syndrome! | Cyproheptadine: serotonin |
| | | | | syndrome (serotonin receptor |
| | | | | antagonist) |
| Tricyclic | Inhibits reuptake of | Readily absorbed, | Small overdose: Mild sedation, | Decontamination |
| Antidepressants | norepinephrine and serotonin | lipophilic, highly protein | transient anorexia | Monitor ECG look for signs of QRS |
| (Amitriptyline, | from synaptic clefts in CNS | bound, variable half-life | | widening |
| Clomipramine) | Block muscarinic, histamine, | | Large overdose: Profound | Control seizures with diazepam or |
| | and alpha-adrenergic | Low margin of safety | sedation, seizures, cardiac | phenobarbital |
| | receptors | | arrhythmias, CV collapse = | |
| | | | leading cause of death | |
| | | | Serious anticholinergic effects: | |
| | | | Mydriasis, blurred vision, dry | |
| | | | mouth, tachycardia, urinary | |
| | | | retention, slowed GI transit time | |
| Sleep Aids | Often benzodiazepines or | Time to onset ∼ 1-2h | Paradoxical CNS stimulation | Early use of emetics: AC + cathartic |
| (Zolpidem, | non-benzodiazepine | | rather than expected depression | - |
| eszopiclone) | hypnotics | Duration of signs ∼ 12 h | Hyperactivity, agitation, | Flumazenil: GABA _A receptor |
| | | | panting, tremors | antagonist *only in severe cases |
| | Potentiate GABA | | Lethargy, weakness, dullness, | |
| | transmission, increase | | ataxia, paresis | Monitor for seizures |
| | frequency of chloride | | Nausea, vomiting, diarrhea, | If paradoxical, do not use benzos, |
| | channel opening and result in | | hyperthermia | phenothiazines or barbiturates are |
| | | | | preferred! |

| | inhibition of neuronal excitation | | | |
|---|--|---|--|--|
| ADHD Drugs (Dextroamphetamine, Methylphenidate) | All amphetamines or similar Sympathomimetic compounds | Stimulate the release of norepinephrine, dopamine, and serotonin Directly stimulate alpha and beta adrenergic receptors | CNS overstimulation, excessive sympathomimetic effects Agitation, panting, tachycardia, tremors, seizures, coma hyperthermia Rarely depression, weakness, and bradycardia | Early emesis Control body temp IVF at 1.5-2x maint Control tachycardia and hypertension (b-blocker) Monitor ECG, body temp, acid/base status and renal function |
| Acetaminophen | COX pathway inhibitor | Most intoxications involve cats since they do not conjugate the drug well Glucuronidation in the liver | Metabolic acidosis possible Cats: Methemoglobin, cyanosis, respiratory distress, Heinz body anemia, hematuria and hemoglobinuria, edema of the face/paws, icterus | Early intervention GID N-acetlycystein is antidotal, helps provide a source of cysteine for glutathione replenishment, improves efficacy of sulfation pathway, binds directly with NAPQI Rate limiting amino acid for glutathione synthesis ASMe Ascorbic acids RBC or oxyglobin Cimetidine Rx coagulopathy if present, methylene blue for MetHb if there are no other options |
| Albuterol | Selective B ₂ agonist Less cardiac stimulation | | Sinus tachycardia HYPOKALEMIA | Propranolol for tachycardia and hypokalemia |

| | Used to treat asthma and | | | Potassium in fluids depending on |
|------------------|---------------------------|-------------------------|--------------------------------|----------------------------------|
| | bronchospasm | | | the severity of the hypokalemia |
| | | | | Good prognosis |
| B-blockers | B-adrenergic antagonists | Rapid absorption | Bradycardia | Decontamination |
| | | Low protein binding | Hypotension | IVF |
| | | Variable metabolism | Seizures | Antidote: isoproterenol |
| | | Short half-life | Respiratory compromise | Vasopressors are NOT |
| | | Renal excretion | Altered mentation/coma | recommended |
| Muscle Relaxants | Centrally acting skeletal | Narrow margin of safety | CNS and respiratory depression | IVF to increase excretion |
| (Baclofen) | muscle relaxant mimics | | | Atropine |
| | GABA | | | Diazepam |
| | | | | Cyproheptadine |

*Serotonin Syndrome

- Best assessed as a totality of signs (toxidrome)
- Autonomic dysfunction, altered mental status, seizures, extrapyramidal syndrome (hyperthermia and muscle rigidity)
- Signs
 - o Generalized weakness, anorexia
 - o Hypersalivation
 - o CNS signs: Agitation, aggression, tremors, ataxia, nystagmus, head tilt, seizures, rigidity, mydriasis
 - Hyperthermia
 - o GI signs: Emesis, diarrhea
 - o CV signs: Hypertension and tachycardia

Direct Acting Adrenergic Agents

- Alpha₁ agonists: vasoconstriction
- Alpha₂ agonists: central control of blood pressure
- Beta₁ agonists: cardiac stimulation (isoproterenol, dobutamine)

• Beta₂ agonists: bronchial relaxation (albuterol)